Found: 17
Select item for more details and to access through your institution.
GRADUATE I AND II: Revisiting the key findings from two Phase III studies evaluating the efficacy and safety of subcutaneous gantenerumab in early Alzheimer's disease (AD).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.082977
- By:
- Publication type:
- Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
- By:
- Publication type:
- Article
Re‐estimation of drug‐specific amyloid removal parameters and the rate constant for pathogenic tau turnover brings the Q‐ATN model into better alignment with recent phase 3 data from gantenerumab and lecanemab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.076222
- By:
- Publication type:
- Article
Open RoAD: Design and baseline characteristics of an open‐label rollover study evaluating long‐term safety and tolerability of subcutaneous gantenerumab in participants with early Alzheimer's disease.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, p. 1, doi. 10.1002/alz.063261
- By:
- Publication type:
- Article
Development of a quantitative semi‐mechanistic model of Alzheimer's disease based on the amyloid/tau/neurodegeneration framework (the Q‐ATN model).
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2023, v. 19, n. 6, p. 2287, doi. 10.1002/alz.12877
- By:
- Publication type:
- Article
Using an external control to contextualize efficacy data from patients with prodromal and mild Alzheimer's disease treated with gantenerumab in SCarlet RoAD and Marguerite RoAD open‐label extension studies.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.061840
- By:
- Publication type:
- Article
Baseline participant characteristics of GRADUATION: a study to evaluate once‐weekly subcutaneous administration of gantenerumab.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 10, p. 1, doi. 10.1002/alz.061781
- By:
- Publication type:
- Article
Gantenerumab treatment increases plasma beta‐amyloid(1–42) and decreases plasma pTau.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.065684
- By:
- Publication type:
- Article
Comparing ARIA‐E severity scales and effects of treatment management thresholds.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 5, p. 1, doi. 10.1002/alz.063848
- By:
- Publication type:
- Article
Linking amyloid to clinical outcome: A quantitative semi‐mechanistic model based on the A/T/N biomarker framework to simulate the natural history of Alzheimer's disease and the effects of anti‐amyloid treatment.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2022, v. 18, n. 3, p. 1, doi. 10.1002/alz.067069
- By:
- Publication type:
- Article
Graduation study design: Evaluation of once‐weekly subcutaneous administration of gantenerumab on brain amyloid load.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2021, v. 17, p. 1, doi. 10.1002/alz.052060
- By:
- Publication type:
- Article
Calibration of a simplified ARIA‐E MRI severity scale suitable for clinical practice: Human neuropathology/imaging‐pathologic correlations.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2020, v. 16, n. 11, p. 1, doi. 10.1002/alz.041110
- By:
- Publication type:
- Article
DT‐01‐02: CONTINUED LARGE AMYLOID PET REDUCTIONS AT 36 MONTHS IN THE GANTENERUMAB OPEN‐LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P1484, doi. 10.1016/j.jalz.2019.08.005
- By:
- Publication type:
- Article
O3‐10‐01: CORRELATION BETWEEN AMYLOID REDUCTION AND CLINICAL OUTCOMES: EXPLORATORY ANALYSES FROM THE GANTENERUMAB SCARLET ROAD AND MARGUERITE ROAD OPEN‐LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2019, v. 15, p. P908, doi. 10.1016/j.jalz.2019.06.4678
- By:
- Publication type:
- Article
O1‐09‐03: 24‐MONTH AMYLOID PET RESULTS OF THE GANTENERUMAB HIGH‐DOSE OPEN LABEL EXTENSION STUDIES.
- Published in:
- Alzheimer's & Dementia: The Journal of the Alzheimer's Association, 2018, v. 14, p. P240, doi. 10.1016/j.jalz.2018.06.2380
- By:
- Publication type:
- Article
Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer's disease: a PET substudy interim analysis.
- Published in:
- Alzheimer's Research & Therapy, 2019, v. 11, n. 1, p. 1, doi. 10.1186/s13195-019-0559-z
- By:
- Publication type:
- Article
Expression of Prostacyclin-Synthase in Human Breast Cancer: Negative Prognostic Factor and Protection against Cell Death In Vitro.
- Published in:
- Mediators of Inflammation, 2015, v. 2015, p. 1, doi. 10.1155/2015/864136
- By:
- Publication type:
- Article